Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases

Med Oncol. 2010 Sep;27(3):938-41. doi: 10.1007/s12032-009-9311-z. Epub 2009 Sep 19.

Abstract

Spontaneous pyopneumothorax is a very rare occurrence, even in cancer treated patients. Here we present two consecutive cases of spontaneous pyopneumothorax that occurred early after initiation of mTOR inhibitors for the treatment of renal cell carcinoma with subpleural pulmonary metastasis. In these two cases, necrosis and excavation of lung metastasis were observed, suggesting their involvement in the pathogenic mechanism of pyopneumothorax. This report extends the available experience of the pulmonary side effects of these novel targeted therapies.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzenesulfonates / administration & dosage
  • Calcitonin / blood
  • Carcinoma, Renal Cell / complications
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / secondary*
  • Carcinoma, Renal Cell / surgery
  • Combined Modality Therapy
  • Disease Susceptibility
  • Everolimus
  • Fatal Outcome
  • Female
  • Humans
  • Indoles / administration & dosage
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary*
  • Male
  • Middle Aged
  • Necrosis
  • Neoplasm Proteins / antagonists & inhibitors*
  • Nephrectomy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pneumonia, Bacterial / complications
  • Pneumothorax / chemically induced*
  • Protein Precursors / blood
  • Pyridines / administration & dosage
  • Pyrroles / administration & dosage
  • Rupture, Spontaneous
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • Sorafenib
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Benzenesulfonates
  • Indoles
  • Neoplasm Proteins
  • Phenylurea Compounds
  • Protein Precursors
  • Pyridines
  • Pyrroles
  • Niacinamide
  • temsirolimus
  • Calcitonin
  • Everolimus
  • Sorafenib
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sunitinib
  • Sirolimus